batiraxcept,cabozantinib
exelixis,aravive
['rcc,(-irccs),(-srcc),(-urcc)', 'batiraxcept', 'cabozantinib', 'biomarker']
encouraging data showing promising activity of batiraxcept (targeting axl) in combination with cabozantinib in mrcc - notably the saxl/gas6 biomarker enriched response (67%). no additive toxicity.. #asco2022 
An Australian oncologist with an interest in GU malignancies, phase 1 trials, cycling and having fun with the family